Want to see HK:6855 full AI Analyst Report?
Ascentage Pharma Group International (6855) Ratios
Ascentage Pharma Group International Ratios
HK:6855's free cash flow for Q2 2026 was $-610.60M. For the 2026 fiscal year, HK:6855's free cash flow was decreased by $-11.70M and operating cash flow was $-598.90M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.79 | 1.26 | 1.44 | 1.86 | 5.22 |
| Quick Ratio | 1.77 | 1.26 | 1.42 | 1.85 | 5.21 |
| Cash Ratio | 1.50 | 1.08 | 1.14 | 1.69 | 4.83 |
| Solvency Ratio | -0.43 | -0.14 | -0.34 | -0.35 | -0.45 |
| Operating Cash Flow Ratio | -0.71 | -0.10 | -0.78 | -0.74 | -1.67 |
| Short-Term Operating Cash Flow Coverage | -0.96 | -0.14 | -1.20 | -1.28 | -15.19 |
| Net Current Asset Value | $ 314.94M | $ -869.49M | $ -1.09B | $ -785.12M | $ 179.96M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.50 | 0.64 | 0.72 | 0.63 | 0.37 |
| Debt-to-Equity Ratio | 1.49 | 6.32 | 29.72 | 4.39 | 0.88 |
| Debt-to-Capital Ratio | 0.60 | 0.86 | 0.97 | 0.81 | 0.47 |
| Long-Term Debt-to-Capital Ratio | 0.36 | 0.77 | 0.95 | 0.76 | 0.45 |
| Financial Leverage Ratio | 2.99 | 9.91 | 41.39 | 6.93 | 2.38 |
| Debt Service Coverage Ratio | -0.86 | -0.37 | -1.05 | -1.48 | -15.32 |
| Interest Coverage Ratio | -22.42 | -5.88 | -9.29 | -16.74 | -55.77 |
| Debt to Market Cap | 0.12 | 0.13 | 0.25 | 0.30 | 0.18 |
| Interest Debt Per Share | 5.71 | 5.74 | 6.70 | 7.00 | 4.32 |
| Net Debt to EBITDA | 0.45 | -1.36 | -0.98 | -0.36 | 0.72 |
| Profitability Margins | |||||
| Gross Profit Margin | 76.41% | 97.03% | 86.24% | 89.51% | 88.08% |
| EBIT Margin | -211.14% | -38.63% | -376.97% | -421.25% | -3343.50% |
| EBITDA Margin | -195.68% | -30.55% | -334.98% | -398.64% | -3281.93% |
| Operating Profit Margin | -211.14% | -38.63% | -401.83% | -421.25% | -3343.50% |
| Pretax Profit Margin | -215.29% | -40.31% | -420.24% | -423.05% | -2981.90% |
| Net Profit Margin | -216.47% | -41.34% | -416.98% | -421.02% | -2803.38% |
| Continuous Operations Profit Margin | -216.50% | -41.37% | -417.02% | -421.02% | -2803.38% |
| Net Income Per EBT | 100.54% | 102.58% | 99.23% | 99.52% | 94.01% |
| EBT Per EBIT | 101.97% | 104.34% | 104.58% | 100.43% | 89.19% |
| Return on Assets (ROA) | -30.53% | -15.49% | -37.02% | -31.20% | -26.61% |
| Return on Equity (ROE) | -91.36% | -153.46% | -1532.08% | -216.05% | -63.37% |
| Return on Capital Employed (ROCE) | -50.87% | -26.10% | -56.95% | -45.32% | -36.18% |
| Return on Invested Capital (ROIC) | -33.25% | -16.98% | -40.55% | -42.89% | -34.66% |
| Return on Tangible Assets | -31.24% | -16.11% | -38.73% | -32.45% | -27.41% |
| Earnings Yield | -7.24% | -3.14% | -13.26% | -14.76% | -13.38% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.86 | 11.79 | 1.52 | 3.86 | 0.52 |
| Payables Turnover | 1.24 | 0.32 | 0.42 | 0.23 | 0.05 |
| Inventory Turnover | 4.61 | 4.41 | 1.89 | 2.33 | 0.85 |
| Fixed Asset Turnover | 0.67 | 1.08 | 0.23 | 0.32 | 0.03 |
| Asset Turnover | 0.14 | 0.37 | 0.09 | 0.07 | 0.01 |
| Working Capital Turnover Ratio | 0.70 | 2.73 | 0.38 | 0.18 | 0.02 |
| Cash Conversion Cycle | -19.72 | -1040.39 | -432.66 | -1334.18 | -6634.91 |
| Days of Sales Outstanding | 196.54 | 30.95 | 239.89 | 94.61 | 705.78 |
| Days of Inventory Outstanding | 79.22 | 82.79 | 193.20 | 156.77 | 431.02 |
| Days of Payables Outstanding | 295.47 | 1154.12 | 865.74 | 1585.55 | 7771.71 |
| Operating Cycle | 275.76 | 113.73 | 433.09 | 251.37 | 1136.80 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.30 | -0.37 | -2.57 | -2.48 | -2.37 |
| Free Cash Flow Per Share | -3.37 | -0.45 | -2.77 | -3.25 | -4.08 |
| Dividend Paid and CapEx Coverage Ratio | -42.59 | -4.58 | -12.77 | -3.22 | -1.39 |
| Capital Expenditure Coverage Ratio | -42.59 | -4.58 | -12.77 | -3.22 | -1.39 |
| Operating Cash Flow Coverage Ratio | -0.59 | -0.07 | -0.40 | -0.36 | -0.56 |
| Operating Cash Flow to Sales Ratio | -2.10 | -0.11 | -3.27 | -3.12 | -21.67 |
| Free Cash Flow Yield | -7.19% | -1.05% | -11.21% | -14.33% | -17.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.80 | -31.80 | -7.54 | -6.78 | -7.47 |
| Price-to-Sales (P/S) Ratio | 29.89 | 13.15 | 31.46 | 28.53 | 209.51 |
| Price-to-Book (P/B) Ratio | 12.61 | 48.81 | 115.58 | 14.64 | 4.74 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.91 | -95.06 | -8.92 | -6.98 | -5.62 |
| Price-to-Operating Cash Flow Ratio | -14.23 | -115.79 | -9.62 | -9.15 | -9.67 |
| Price-to-Earnings Growth (PEG) Ratio | -0.09 | 0.54 | 3.61 | -0.74 | 3.35 |
| Enterprise Value Multiple | -14.82 | -44.39 | -10.37 | -7.52 | -5.66 |
| Enterprise Value | 16.22B | 13.30B | 7.71B | 6.28B | 5.19B |
| EV to EBITDA | -14.82 | -44.39 | -10.37 | -7.52 | -5.66 |
| EV to Sales | 29.01 | 13.56 | 34.73 | 29.96 | 185.88 |
| EV to Free Cash Flow | -13.50 | -98.06 | -9.85 | -7.33 | -4.99 |
| EV to Operating Cash Flow | -13.82 | -119.45 | -10.62 | -9.61 | -8.58 |
| Tangible Book Value Per Share | 3.49 | 0.57 | -0.14 | 1.14 | 4.52 |
| Shareholders’ Equity Per Share | 3.72 | 0.87 | 0.21 | 1.55 | 4.85 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.03 | 0.01 | 0.00 | 0.06 |
| Revenue Per Share | 1.57 | 3.25 | 0.79 | 0.80 | 0.11 |
| Net Income Per Share | -3.40 | -1.34 | -3.28 | -3.35 | -3.07 |
| Tax Burden | 1.01 | 1.03 | 0.99 | 1.00 | 0.94 |
| Interest Burden | 1.02 | 1.04 | 1.11 | 1.00 | 0.89 |
| Research & Development to Revenue | 1.94 | 0.97 | 3.18 | 3.54 | 27.46 |
| SG&A to Revenue | 0.94 | 0.39 | 0.82 | 0.81 | 5.13 |
| Stock-Based Compensation to Revenue | 0.04 | 0.02 | 0.14 | 0.11 | 1.68 |
| Income Quality | 0.95 | 0.27 | 0.78 | 0.74 | 0.77 |
Currency in CNY
